Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations
Expert Review of Clinical Pharmacology · 15.11.2026 · 1-18
DOI: 10.1080/17512433.2026.2763168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 15.11.2026. Verfasst von Federica Di Vincenzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit - Centro di Malattie dell'Apparato Digerente (CeMAD), UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gem…. Die Arbeit nennt 112 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Crohn's disease (CD) remains a major clinical challenge, since many patients fail biologics or lose response. Selective IL-23p19 blockade is mechanistically attractive, targeting the IL-23/Th17 axis while preserving IL-12-dependent host defense. Risankizumab, the first selective IL-23p19 inhibitor approved for CD, is increasingly used in advanced therapy-experienced patients. AREAS COVERED: This narrative review summarizes risankizumab pharmacology, pivotal trial data, real-world effectiveness and safety in moderate-to-severe CD, emphasizing biologic-experienced and multiply exposed populations, based on PubMed, Scopus and Google Scholar searches (from inception to October 2026). It also examines difficult-to-treat phenotypes (postoperative recurrence, CD of the pouch, perianal, fistulising and stricturing disease, extraintestinal manifestations) and compares risankizumab with other IL-23p19 inhibitors. Positioning is discussed in light of the SEQUENCE trial and 2025 ACG and AGA guidelines, together with unresolved issues: special populations, predictive biomarkers and investigational combination therapy. EXPERT OPINION: Risankizumab is not a universal solution for refractory CD, but it is one of the best-supported options after anti-TNF failure, particularly for endoscopic outcomes. Evidence in multiply exposed patients and difficult-to-treat phenotypes is largely observational, and superiority over anti-TNF agents as first-line therapy is unproven. Major gaps persist in fistulising disease, special populations, head-to-head comparisons, predictive biomarkers, and sequencing or combination strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IBD Unit - Centro di Malattie dell'Apparato Digerente (CeMAD), UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Università Cattolica del Sacro Cuore, Rome, Italy.
- IBD Center, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
ORCID-Profile: Federica Di Vincenzo, Giuseppe Privitera, Lucrezia Laterza
Zitieren
APA
Di Vincenzo, F., Iaccarino, J., Privitera, G., Bezzio, C., Laterza, L., Scaldaferri, F., & Armuzzi, A. (2026). Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations. Expert Review of Clinical Pharmacology, 1-18. https://doi.org/10.1080/17512433.2026.2763168
Vancouver
Di Vincenzo F, Iaccarino J, Privitera G, Bezzio C, Laterza L, Scaldaferri F, et al. Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations. Expert Review of Clinical Pharmacology. 2026:1-18. doi:10.1080/17512433.2026.2763168
BibTeX
@article{DiVincenzo2026,
author = {Di Vincenzo, Federica and Iaccarino, Jacopo and Privitera, Giuseppe and Bezzio, Cristina and Laterza, Lucrezia and Scaldaferri, Franco and Armuzzi, Alessandro},
title = {Selective IL-23p19 blockade in moderate-to-severe Crohn’s disease: the role and limitations of risankizumab in complex populations},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
pages = {1--18},
doi = {10.1080/17512433.2026.2763168}
}
EUVIMED